Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Gastrointestinal Neurology Clinical Trials

Linaclotide meets all endpoints in Phase III IBS trial

This article was originally published in Scrip

Executive Summary

Ironwood/Forest/Almirall's guanylate cyclase agonist linaclotide met all its primary endpoints in its first Phase III trial in irritable bowel syndrome with constipation (IBS-C).. Results from a second, ongoing trial in IBS-C are due by the end of the year. Ironwood and Forest plan to submit an NDA for the drug in the US in mid-2011. Almirall has rights to linaclotide in Europe and the Commonwealth of Independent States (CIS) and will determine EU filing dates following the completion of the second trial.

Table

View full table

Topics

Related Companies

Tags:
Gastrointestinal Neurology Clinical Trials
Latest Headlines

Novartis Looks To Maintain A Lead In Radiopharmaceuticals With Mariana Takeout

Dupixent COPD Approval Could Be Delayed, Regeneron Cautions

Competition Forces Price Cuts, But Novo Nordisk Is Unstoppable

Metagenomi Looks For Upside To Moderna’s Exit

See All
UsernamePublicRestriction

Register

SC010158

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By